Tests VV-14303 gene therapy for fatty liver disease called MASH
Tests a gene therapy, VV-14303, in adults with MASH fatty liver disease.
Plain-language title generated from the registry record
Registry title: A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)
Key facts
- Where
- Auckland, New ZealandSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07732400, who can take part
Where in New Zealand
- AucklandAuckland, New ZealandNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kriya Therapeutics, Inc.
- Trial code
- NCT07732400
- Record updated
- 1 September 2026
- Original description
A Study of VV-14303 for the Treatment of Metabolic dysfunction-associated steatohepatitis (MASH)Read full original descriptionShow less
A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of VV-14303, an Adeno-associated Virus Vector-mediated Fibroblast Growth Factor 21 (FGF21) Gene Therapy, in Adults With Metabolic Dysfunction-associated Steatohepatitis (MASH)
A Study of VV-14303 for the Treatment of Metabolic dysfunction-associated steatohepatitis (MASH)
Inclusion: Participant is capable of providing signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol; Must be 18 to 75 years of age (inclusive) at Screening; Body Mass Index (BMI) of 25 to <40 kg/m2 (inclusive); Male participants must agree to use a highly effective contraception during the Treatment Period and at least 12 months after administration of VV-14303. Female participants must not be a woman of child-bearing potential (WOCBP); Biopsy-confirmed MASH; Previous history or presence of ≥2 of the following metabolic risk factors: obesity (BMI ≥25 kg/m²), hypertension (blood pressure [BP] ≥140/90 mmHg or on antihypertensive medication), dyslipidemia (triglycerides ≥150 mg/dL or high-density lipoprotein cholesterol [HDL-C] <40 mg/dL in men/<50 mg/dL in women or on lipid-lowering therapy), type 2 diabetes mellitus; Must be willing to refrain from the donation of blood, plasma, platelets, eggs, or sperm during the 12-month post-treatment follow-up period.
Exclusion: Use of Resmetirom that has not been stable for at least 6 months prior to Screening visit; Any medical, cognitive, or psychiatric condition that, in the opinion of the Investigator, could contraindicate the use of the investigational drug, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or would make the participant an unsafe study candidate; History of major trauma to the muscle(s) intended for IM injection meeting any of the following criteria:; Within 6 months prior to Screening, or; At any timepoint prior to Screening with continued neurologic or musculoskeletal symptoms; Prior participation in any systemic experimental treatment or receiving any other systemic investigational treatment including within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of Screening; Any vaccination or planned vaccination 30 days prior to dosing, or planned vaccination 8 weeks post dosing; Previously received AAV or adenoviral therapy or participation in any previous gene therapy trial; Presence of alternate and/or additional liver disease etiologies at Screening, including but not limited to chronic viral hepatitis, autoimmune hepatitis; Use of treatments for metabolic syndrome management, including oral antidiabetic drugs (OADs) (e.g., metformin), incretin mimetics (GLP-1 receptor agonists or GLP-1/gastric inhibitory polypeptide [GIP] agonists) or other glucose-lowering agents that has not been stable for at least 6 months prior to Screening; Type 1 diabetes, or poorly controlled type 2 diabetes (HbA1c > 8.0% at Screening).